Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-33 in Relapsed/Refractory AML
NCT01864902Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2013
- Primary completion
- Apr 2016
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD33 CAR-T in acute myeloid leukemia (AML), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01864902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864902.